DGCI Approval to Covaxin for children aged between 2-18 years awaited after evaluation of data Mukesh Ranjan June 4, 2022
DGCI DGCI approves Phase 2/3 clinical trials of COVAXIN for 2-18 years old Mukesh Ranjan June 4, 2022
DGCI Zydus’ Virafin gets emergency use approval for treating moderate COVID-19 cases Mukesh Ranjan June 4, 2022
